tiprankstipranks
ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ:ACAD
US Market
ACAD
ACADIA Pharmaceuticals
RESEARCH TOOLSreports
Want to see ACAD full AI Analyst Report?

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

2,438 Followers
See the Price Targets and Ratings of:

ACAD Analyst Ratings

Strong Buy
14Ratings
Strong Buy
11 Buy
3 Hold
0 Sell
Based on 14 analysts giving stock ratings to
ACADIA
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACAD Stock 12 Month Forecast

Average Price Target

$32.33
▲(45.84% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $32.33 with a high forecast of $38.00 and a low forecast of $23.00. The average price target represents a 45.84% change from the last price of $22.17.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","26":"$26","39":"$39","19.5":"$19.5","32.5":"$32.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.333333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,19.5,26,32.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.95,23.184615384615384,24.41923076923077,25.653846153846153,26.888461538461538,28.123076923076923,29.357692307692307,30.592307692307692,31.826923076923077,33.06153846153846,34.29615384615384,35.53076923076923,36.76538461538462,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.95,22.74871794871795,23.547435897435896,24.346153846153847,25.144871794871797,25.943589743589744,26.742307692307694,27.54102564102564,28.33974358974359,29.13846153846154,29.93717948717949,30.73589743589744,31.534615384615385,{"y":32.333333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.95,22.03076923076923,22.111538461538462,22.192307692307693,22.27307692307692,22.353846153846153,22.434615384615384,22.515384615384615,22.596153846153847,22.676923076923078,22.757692307692306,22.838461538461537,22.91923076923077,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.465,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$38.00Average Price Target$32.33Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on ACAD
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$23
Hold
3.74%
Upside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
BMO Capital Analyst forecast on ACAD
Evan Seigerman
BMO Capital
BMO Capital
$34
Buy
53.36%
Upside
Reiterated
05/11/26
BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
Citi Analyst forecast on ACAD
Yigal Nochomovitz
Citi
Citi
$33→$32
Buy
44.34%
Upside
Reiterated
05/08/26
Acadia Pharmaceuticals price target lowered to $32 from $33 at CitiAcadia Pharmaceuticals price target lowered to $32 from $33 at Citi
Guggenheim Analyst forecast on ACAD
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/07/26
Guggenheim Keeps Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
TD Cowen Analyst forecast on ACAD
Ritu Baral
TD Cowen
TD Cowen
$37
Buy
66.89%
Upside
Reiterated
05/07/26
Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (NASDAQ: ACAD), Qiagen (NYSE: QGEN) and Alcon (NYSE: ALC)
Needham Analyst forecast on ACAD
Ami Fadia
Needham
Needham
$40→$38
Buy
71.40%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (Other OTC: KSPHF), Recursion Pharmaceuticals (NASDAQ: RXRX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Stifel Nicolaus Analyst forecast on ACAD
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$24
Hold
8.25%
Upside
Reiterated
05/07/26
Stifel Nicolaus Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
H.C. Wainwright Analyst forecast on ACAD
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$37
Buy
66.89%
Upside
Reiterated
05/07/26
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained
Bank of America Securities Analyst forecast on ACAD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (NASDAQ: EVO), Vaxcyte (NASDAQ: PCVX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Mizuho Securities Analyst forecast on ACAD
Uy Ear
Mizuho Securities
Mizuho Securities
$35
Buy
57.87%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD) and Siemens Healthineers AG (Other OTC: SEMHF)
Wolfe Research Analyst forecast on ACAD
Rudy Li
Wolfe Research
Wolfe Research
$33
Buy
48.85%
Upside
Reiterated
05/06/26
ACADIA Pharmaceuticals (ACAD) Gets a Buy from Wolfe Research
RBC Capital Analyst forecast on ACAD
Brian Abrahams
RBC Capital
RBC Capital
$29
Buy
30.81%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Revolution Medicines (NASDAQ: RVMD)
Canaccord Genuity Analyst forecast on ACAD
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$32
Buy
44.34%
Upside
Reiterated
05/06/26
ACADIA: Buy Rating Reiterated on Nuplazid/Daybue Upside and Remlifanserin Optionality; $32 DCF-Based Price Target Maintained
J.P. Morgan Analyst forecast on ACAD
Tessa Romero
J.P. Morgan
J.P. Morgan
$34
Buy
53.36%
Upside
Assigned
03/04/26
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorganAcadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
Citizens JMP Analyst forecast on ACAD
Jason Butler
Citizens JMP
Citizens JMP
$34→$35
Buy
57.87%
Upside
Reiterated
02/26/26
Acadia Pharmaceuticals price target raised to $35 from $34 at CitizensAcadia Pharmaceuticals price target raised to $35 from $34 at Citizens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on ACAD
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$23
Hold
3.74%
Upside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
BMO Capital Analyst forecast on ACAD
Evan Seigerman
BMO Capital
BMO Capital
$34
Buy
53.36%
Upside
Reiterated
05/11/26
BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
Citi Analyst forecast on ACAD
Yigal Nochomovitz
Citi
Citi
$33→$32
Buy
44.34%
Upside
Reiterated
05/08/26
Acadia Pharmaceuticals price target lowered to $32 from $33 at CitiAcadia Pharmaceuticals price target lowered to $32 from $33 at Citi
Guggenheim Analyst forecast on ACAD
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/07/26
Guggenheim Keeps Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
TD Cowen Analyst forecast on ACAD
Ritu Baral
TD Cowen
TD Cowen
$37
Buy
66.89%
Upside
Reiterated
05/07/26
Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (NASDAQ: ACAD), Qiagen (NYSE: QGEN) and Alcon (NYSE: ALC)
Needham Analyst forecast on ACAD
Ami Fadia
Needham
Needham
$40→$38
Buy
71.40%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (Other OTC: KSPHF), Recursion Pharmaceuticals (NASDAQ: RXRX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Stifel Nicolaus Analyst forecast on ACAD
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$24
Hold
8.25%
Upside
Reiterated
05/07/26
Stifel Nicolaus Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
H.C. Wainwright Analyst forecast on ACAD
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$37
Buy
66.89%
Upside
Reiterated
05/07/26
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained
Bank of America Securities Analyst forecast on ACAD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (NASDAQ: EVO), Vaxcyte (NASDAQ: PCVX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Mizuho Securities Analyst forecast on ACAD
Uy Ear
Mizuho Securities
Mizuho Securities
$35
Buy
57.87%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD) and Siemens Healthineers AG (Other OTC: SEMHF)
Wolfe Research Analyst forecast on ACAD
Rudy Li
Wolfe Research
Wolfe Research
$33
Buy
48.85%
Upside
Reiterated
05/06/26
ACADIA Pharmaceuticals (ACAD) Gets a Buy from Wolfe Research
RBC Capital Analyst forecast on ACAD
Brian Abrahams
RBC Capital
RBC Capital
$29
Buy
30.81%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Revolution Medicines (NASDAQ: RVMD)
Canaccord Genuity Analyst forecast on ACAD
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$32
Buy
44.34%
Upside
Reiterated
05/06/26
ACADIA: Buy Rating Reiterated on Nuplazid/Daybue Upside and Remlifanserin Optionality; $32 DCF-Based Price Target Maintained
J.P. Morgan Analyst forecast on ACAD
Tessa Romero
J.P. Morgan
J.P. Morgan
$34
Buy
53.36%
Upside
Assigned
03/04/26
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorganAcadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
Citizens JMP Analyst forecast on ACAD
Jason Butler
Citizens JMP
Citizens JMP
$34→$35
Buy
57.87%
Upside
Reiterated
02/26/26
Acadia Pharmaceuticals price target raised to $35 from $34 at CitizensAcadia Pharmaceuticals price target raised to $35 from $34 at Citizens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

3 Months
Tessa RomeroJ.P. Morgan
Success Rate
9/13 ratings generated profit
69%
Average Return
+8.73%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.73% per trade.
1 Year
Jason ButlerCitizens JMP
Success Rate
13/28 ratings generated profit
46%
Average Return
+5.71%
Copying Jason Butler's trades and holding each position for 1 Year would result in 46.43% of your transactions generating a profit, with an average return of +5.71% per trade.
2 Years
Ami FadiaNeedham
Success Rate
10/17 ratings generated profit
59%
Average Return
+11.50%
Copying Ami Fadia's trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +11.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACAD Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
4
5
4
7
Buy
14
19
19
16
12
Hold
6
10
9
8
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
33
33
28
23
In the current month, ACAD has received 19 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ACAD average Analyst price target in the past 3 months is 32.33.
Each month's total comprises the sum of three months' worth of ratings.

ACAD Financial Forecast

ACAD Earnings Forecast

Next quarter’s earnings estimate for ACAD is $0.06 with a range of -$0.05 to $0.20. The previous quarter’s EPS was $0.02. ACAD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.
Next quarter’s earnings estimate for ACAD is $0.06 with a range of -$0.05 to $0.20. The previous quarter’s EPS was $0.02. ACAD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.

ACAD Sales Forecast

Next quarter’s sales forecast for ACAD is $296.63M with a range of $280.23M to $312.70M. The previous quarter’s sales results were $268.06M. ACAD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.
Next quarter’s sales forecast for ACAD is $296.63M with a range of $280.23M to $312.70M. The previous quarter’s sales results were $268.06M. ACAD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.

ACAD Stock Forecast FAQ

What is ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals Inc.’s 12-month average price target is 32.33.
    What is ACAD’s upside potential, based on the analysts’ average price target?
    ACADIA Pharmaceuticals Inc. has 45.84% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACAD a Buy, Sell or Hold?
          ACADIA Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
            What is ACADIA Pharmaceuticals Inc.’s price target?
            The average price target for ACADIA Pharmaceuticals Inc. is 32.33. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $38.00 ,the lowest forecast is $23.00. The average price target represents 45.84% Increase from the current price of $22.17.
              What do analysts say about ACADIA Pharmaceuticals Inc.?
              ACADIA Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of ACAD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.